LMATLeMaitre Vascular Inc.
−1.1% today · −6.5% over a year
7/10 A 1–10 summary of how an instrument compares with similar ones (same sector and region) by published rules. It describes today's data; it is not a price forecast. More in the glossary → «Balanced» — higher than 77% of the instruments we score
Stability, Dividend safety: among the best of its peers; priced lower than most peers. Dividend yield 1.15%.
LeMaitre Vascular Inc. (LMAT) belongs to the Health care sector and is listed on Nasdaq; country: United States. Its market value is about €1.7B. Over the past 12 months the price changed by −6.5%, with an annualised volatility of 46% and a largest fall of 33%. The dividend has been raised 15 years in a row.
Smart Score
How it is scored →The Smart Score (1–10) describes how this instrument compares with its peers on published, rules-based measures of value, quality, trend, stability and dividend safety. It is not a forecast and not personal advice.
Compared with: Health care companies in USA (n = 337)
Current rating first published: · last recomputed · rating log
Factor scores
Percentiles within the peer group (100 = the best of its peers); dividend safety in points.
Main drivers
- Net debt / EBITDAsupports the score · better than 91% of peers
- Max drawdown (3 y)supports the score · better than 90% of peers
- Gross profit growth / assets (5 y)supports the score · better than 69% of peers
Red flags and notes
No red flagsNone of our published warning rules is triggered right now.
Price chart
Interactive chart by TradingView: exchange prices are delayed, crypto and currencies are live.
Key metrics
Valuation
- P/E
- 28.9
- P/B
- 4.5
- P/S
- 7.2
- EV/EBIT
- 21.8
- Free-cash-flow yield
- 3.9%
- Market cap (EUR)
- €1.7B
Profitability and debt
- Return on equity
- 16.8%
- Return on invested capital
- 11.2%
- Gross margin
- 72.9%
- Net debt / EBITDA
- −2.36
Dividends
- Dividend yield
- 1.15%
- Payout ratio
- 33%
- 5-year dividend growth (per year)
- 17.5%
- Years of dividend growth
- 15
Returns and risk
- 1 day
- −1.1%
- 1 month
- +0.6%
- 1 year
- −6.5%
- Volatility, 1 yr
- 45.8%
- Max drawdown, 1 yr
- −32.5%
- Beta
- 0.71
Ratios from SEC filings and end-of-day prices; returns are price changes without dividends.
Similar companies
Same sector and region, closest in market value.
| MLYSMineralys Therapeutics Inc. | —/10 | 0.0% | −47.4% |
|---|---|---|---|
| XRAYDentsply Sirona | 2/10 | 1.7% | −26.7% |
| ZBIOZenas BioPharma Inc. | 1/10 | 0.0% | −4.7% |
| NTLAIntellia Therapeutics Inc | 1/10 | 0.0% | −4.6% |
| TRVITrevi Therapeutics Inc. | 1/10 | 0.0% | 28.4% |
| WGSGeneDx Holdings Corp. | 2/10 | 0.0% | −52.9% |
| XERSXeris Biopharma Holdings Inc. | 4/10 | 0.0% | 15.3% |
| AMNAMN Healthcare Services Inc | 9/10 | 0.0% | 125.4% |
News and filings
- LEMAITRE VASCULAR INC: 8-K — Director or officer change
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 16 Oct 2026
- LEMAITRE VASCULAR INC: 10-Q — Quarterly report for the period ending 30 Jun 2026
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 5 Aug 2026
- LEMAITRE VASCULAR INC: 8-K — Results of operations
A filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.SEC EDGAR · Filing · 5 Aug 2026
What the marks mean
- FactA filing (SEC EDGAR) or an exchange notice (Moscow Exchange): the issuer's or the exchange's own statement.
- Media reportA headline from a named media outlet. We link to it and do not check it.
- RumourUnconfirmed: the headline itself hedges (“reportedly”, “sources say”, “in talks”), names no publisher, or comes from a news aggregator or an automated republisher.
Source: Filings: U.S. SEC EDGAR. The tone is scored automatically from the headline and can be wrong.
Score changes in the last 12 months
Every published rating and change, logged when it was published (EU Market Abuse Regulation).
Show the log: 3 entries
| Date | Event | Balanced | Growth · Income | Warnings | Price at publication |
|---|---|---|---|---|---|
| Rating change | 7/10 | 7 · 7 | — | Available with Invest Pro | |
| Rating change | 8 → 7/10 | 7 · 8 | — | Available with Invest Pro | |
| First rating | 8/10 | 7 · 8 | — | Available with Invest Pro |
Ratings are rules-based descriptions, valid until the next scoring run (about 06:20 and 21:50 UTC) and the same for every visitor.
Withdraw from contract here · EU consumers: 14 days to withdraw from a purchase.